Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2007-2013

ABSTRACT

Background: - After allogeneic (donor) stem cell transplantation, a new immune system grows in the patient from the transplanted donor stem cells and lymphocytes (type of immune cell). Donor lymphocytes, unlike the patient s own lymphocytes, often can recognize the patient s tumor cells as being foreign and destroy them. - It is thought that tumor shrinkage after stem cell transplantation is the result of donor T lymphocytes, or T cells. Some studies show that patients with tumors that have T cells are better able to keep tumor growth in check. - Patients who have had donor stem cell transplantation may have donor T cells in their tumors that can recognize and fight their cancer. Compared with donor T cells taken directly from the donor and infused into the patient, donor T cells found in patients tumors may be specific for the cancer cells and thus better able to attack tumor. Also, because the T cells found their way to the tumor, they may be less likely to recognize and attack non-tumor tissues than the T cells given in donor lymphocyte infusions. - The T cells may be especially effective at controlling tumor if they are given an additional stimulus to become active. Costimulation is the name of the body s natural process for providing an extra stimulus, and can be performed on cells in the laboratory. Costimulation can produce large numbers of activated cells that may be able to attack cancer cells and shrink tumors. Objectives: -To evaluate the ability of lymphocytes found in tumors from patients who have received donor stem cell transplants to control their tumor growth. Eligibility: -Patients between 18 and 75 years of age with a B-cell cancer that has continued to grow or recurred after remission following allogeneic stem cell transplantation. This includes patients who have received transplants from unrelated donors and cord blood. Design: - Immune cells are collected from patients blood and blood from their stem cell donor. - Patients undergo surgery to remove their tumor and a small piece of skin. In the laboratory, donor T cells are isolated from the tumor and costimulated to expand the number of cells and activate them. - The expanded, activated T cells as infused into the patient. - Patients have a needle biopsy and possibly surgery to remove a sample of remaining tumor for research studies. - Patients are followed at the NIH clinic 48 hours after the cell infusion, and again at 1, 2, 4, 8 and 12 weeks after the infusion. Tumor size is monitored every month with CT scans, and possibly also with a PET or bone marrow aspiration and biopsy, for the first 3 months after the cells are infused. Thereafter, visits are less frequent (every 3 months, then every 6 months, and then yearly) during a minimum 5-year follow-up. Detailed Description Background: - The prognosis for patients with B-cell lymphoid malignancies (BCL) with relapse or refractory disease after allogeneic hematopoietic stem cell transplantation (AlloHSCT) is poor. Effective therapy for patients who fail withdrawal of immune suppression and administration of donor lymphocyte infusions (DLI) has not been identified. - In the setting of recurrent or refractory BCL, the immunologic graft-versus-tumor (GVT) effect generated by unmanipulated donor lymphocytes is often not durable and can be accompanied by graft-versus-host disease (GVHD). - We have hypothesized that lymphocytes found in tumor after alloHSCT are of donor origin, and because they are tumor-derived, they may be tumor-specific in their homing and antigen specificity characteristics. Similarly, inpatients with bone marrow involvement with tumor, the marrow may be enriched with similarly tumor-specific T cells. Further, activation and expansion of these cells through CD3/CD28 costimulation may yield a more effective form of cell therapy than DLI after alloHSCT, with enhanced GVT effects and less GVHD. Objectives: - To evaluate the feasibility of isolating and expanding clinically relevant numbers of TDL from patients after alloHSCT. - To determine the safety, vis-a-vis infusion toxicities and/or GVHD, of administering TDL. Eligibility: - Adults with B cell malignancies with tumor that has not responded to successful T cell engraftment after alloHSCT, withdrawal of immune suppression and administration of donor lymphocyte infusion will be eligible for this trial. - Subjects must have a minimum of 1.5 cm of accessible tumor which is amenable to resection with minimal surgical morbidity and/or bone marrow tumor involvement. Design: - Subjects will have accessible lesion surgically resected and/or harvested via bone marrow aspiration. - Lymphocytes will be liberated and expanded using a co-stimulatory approach with anti-CD3/CD28 magnetic beads to generate TDL and/or marrow-TDL. - 1.0 x 10(6) - 1.0 x 10(8) TDL will be administered. - Subjects will be monitored for the development of infusion reactions (in-hospital for 24 hours after infusion), GVHD (weekly for four weeks then monthly) and tumor responses (monthly). - Two cohorts will be enrolled, with an arm evaluating TDL from resected tumor and an arm to evaluate marrow-TDL from tumor-involved bone marrow. For the TDL arm, 15 to 18 patients and up to 18 donors will be enrolled; for the marrow-TDL arem, 15 patients and up to 15 donors will be enrolled. Both arms will test the primary endpoints of feasibility (with at least 11 of 15 tumors yielding 1.0 x 10(6) TDL/kg meeting defined release criteria) and safety (primarily defined as having a no greater risk of developing grade II-IV acute GVHD by day 28 as standard therapy with unmanipulated DLI). More... »

URL

https://clinicaltrials.gov/show/NCT01445132

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Background: - After allogeneic (donor) stem cell transplantation, a new immune system grows in the patient from the transplanted donor stem cells and lymphocytes (type of immune cell). Donor lymphocytes, unlike the patient s own lymphocytes, often can recognize the patient s tumor cells as being foreign and destroy them. - It is thought that tumor shrinkage after stem cell transplantation is the result of donor T lymphocytes, or T cells. Some studies show that patients with tumors that have T cells are better able to keep tumor growth in check. - Patients who have had donor stem cell transplantation may have donor T cells in their tumors that can recognize and fight their cancer. Compared with donor T cells taken directly from the donor and infused into the patient, donor T cells found in patients tumors may be specific for the cancer cells and thus better able to attack tumor. Also, because the T cells found their way to the tumor, they may be less likely to recognize and attack non-tumor tissues than the T cells given in donor lymphocyte infusions. - The T cells may be especially effective at controlling tumor if they are given an additional stimulus to become active. Costimulation is the name of the body s natural process for providing an extra stimulus, and can be performed on cells in the laboratory. Costimulation can produce large numbers of activated cells that may be able to attack cancer cells and shrink tumors. Objectives: -To evaluate the ability of lymphocytes found in tumors from patients who have received donor stem cell transplants to control their tumor growth. Eligibility: -Patients between 18 and 75 years of age with a B-cell cancer that has continued to grow or recurred after remission following allogeneic stem cell transplantation. This includes patients who have received transplants from unrelated donors and cord blood. Design: - Immune cells are collected from patients blood and blood from their stem cell donor. - Patients undergo surgery to remove their tumor and a small piece of skin. In the laboratory, donor T cells are isolated from the tumor and costimulated to expand the number of cells and activate them. - The expanded, activated T cells as infused into the patient. - Patients have a needle biopsy and possibly surgery to remove a sample of remaining tumor for research studies. - Patients are followed at the NIH clinic 48 hours after the cell infusion, and again at 1, 2, 4, 8 and 12 weeks after the infusion. Tumor size is monitored every month with CT scans, and possibly also with a PET or bone marrow aspiration and biopsy, for the first 3 months after the cells are infused. Thereafter, visits are less frequent (every 3 months, then every 6 months, and then yearly) during a minimum 5-year follow-up.\n\nDetailed Description\nBackground: - The prognosis for patients with B-cell lymphoid malignancies (BCL) with relapse or refractory disease after allogeneic hematopoietic stem cell transplantation (AlloHSCT) is poor. Effective therapy for patients who fail withdrawal of immune suppression and administration of donor lymphocyte infusions (DLI) has not been identified. - In the setting of recurrent or refractory BCL, the immunologic graft-versus-tumor (GVT) effect generated by unmanipulated donor lymphocytes is often not durable and can be accompanied by graft-versus-host disease (GVHD). - We have hypothesized that lymphocytes found in tumor after alloHSCT are of donor origin, and because they are tumor-derived, they may be tumor-specific in their homing and antigen specificity characteristics. Similarly, inpatients with bone marrow involvement with tumor, the marrow may be enriched with similarly tumor-specific T cells. Further, activation and expansion of these cells through CD3/CD28 costimulation may yield a more effective form of cell therapy than DLI after alloHSCT, with enhanced GVT effects and less GVHD. Objectives: - To evaluate the feasibility of isolating and expanding clinically relevant numbers of TDL from patients after alloHSCT. - To determine the safety, vis-a-vis infusion toxicities and/or GVHD, of administering TDL. Eligibility: - Adults with B cell malignancies with tumor that has not responded to successful T cell engraftment after alloHSCT, withdrawal of immune suppression and administration of donor lymphocyte infusion will be eligible for this trial. - Subjects must have a minimum of 1.5 cm of accessible tumor which is amenable to resection with minimal surgical morbidity and/or bone marrow tumor involvement. Design: - Subjects will have accessible lesion surgically resected and/or harvested via bone marrow aspiration. - Lymphocytes will be liberated and expanded using a co-stimulatory approach with anti-CD3/CD28 magnetic beads to generate TDL and/or marrow-TDL. - 1.0 x 10(6) - 1.0 x 10(8) TDL will be administered. - Subjects will be monitored for the development of infusion reactions (in-hospital for 24 hours after infusion), GVHD (weekly for four weeks then monthly) and tumor responses (monthly). - Two cohorts will be enrolled, with an arm evaluating TDL from resected tumor and an arm to evaluate marrow-TDL from tumor-involved bone marrow. For the TDL arm, 15 to 18 patients and up to 18 donors will be enrolled; for the marrow-TDL arem, 15 patients and up to 15 donors will be enrolled. Both arms will test the primary endpoints of feasibility (with at least 11 of 15 tumors yielding 1.0 x 10(6) TDL/kg meeting defined release criteria) and safety (primarily defined as having a no greater risk of developing grade II-IV acute GVHD by day 28 as standard therapy with unmanipulated DLI).", 
    "endDate": "2013-04-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01445132", 
    "keywords": [
      "adoptive cell therapy", 
      "allogeneic hematopoietic stem cell transplantation", 
      "lymphocyte", 
      "Tissue Donor", 
      "stem cell transplantation", 
      "immune system", 
      "patient", 
      "donor stem cell", 
      "immune cell", 
      "donor lymphocyte", 
      "tumor cell", 
      "tumor shrinkage", 
      "T lymphocyte", 
      "T cell", 
      "Neoplasm", 
      "tumor growth", 
      "check", 
      "donor T cell", 
      "fight", 
      "patient tumor", 
      "cancer cell", 
      "attack", 
      "non-tumor tissue", 
      "donor lymphocyte infusion", 
      "additional stimulus", 
      "costimulation", 
      "name", 
      "body", 
      "natural process", 
      "stimulus", 
      "cell", 
      "laboratory", 
      "large number", 
      "activated cell", 
      "attack cancer cell", 
      "shrink", 
      "stem cell transplant", 
      "control", 
      "eligibility", 
      "age", 
      "cell cancer", 
      "remission", 
      "allogeneic stem cell transplantation", 
      "Transplant", 
      "unrelated donor", 
      "Fetal Blood", 
      "patient blood", 
      "blood", 
      "stem cell", 
      "General Surgery", 
      "small piece", 
      "skin", 
      "activated T cell", 
      "needle biopsy", 
      "sample", 
      "research study", 
      "clinic", 
      "infusion", 
      "tumor size", 
      "CT", 
      "PET", 
      "bone marrow aspiration", 
      "biopsy", 
      "visit", 
      "lymphoid malignancy", 
      "Recurrence", 
      "refractory disease", 
      "effective therapy", 
      "withdrawal", 
      "immune suppression", 
      "Organization and Administration", 
      "setting", 
      "graft-versus-tumor", 
      "Graft vs Host Disease", 
      "donor origin", 
      "homing", 
      "antigen specificity", 
      "inpatient", 
      "bone marrow", 
      "tumor-specific T cell", 
      "expansion", 
      "effective form", 
      "Cell- and Tissue-Based Therapy", 
      "graft-versus-tumor effect", 
      "graft-versus-host-disease", 
      "feasibility", 
      "safety", 
      "adult", 
      "B-cell malignancy", 
      "cell engraftment", 
      "trial", 
      "cm", 
      "resection", 
      "morbidity", 
      "lesion", 
      "CO", 
      "magnetic bead", 
      "development", 
      "tumor response", 
      "cohort", 
      "arm", 
      "resected tumor", 
      "primary endpoint", 
      "meeting", 
      "criterion", 
      "great risk", 
      "acute graft-versus-host disease", 
      "standard therapy"
    ], 
    "name": "Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01445132"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00011.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.48336.3a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.410305.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2007-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1073/pnas.92.25.11810", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006947674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199304083281404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043239598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1705074", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053742519", 
          "https://doi.org/10.1038/sj.bmt.1705074"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01445132"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01445132'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01445132'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01445132'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01445132'


 

This table displays all metadata directly associated to this object as RDF triples.

145 TRIPLES      16 PREDICATES      129 URIs      117 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01445132 schema:about anzsrc-for:3048
2 anzsrc-for:3103
3 anzsrc-for:3142
4 schema:description Background: - After allogeneic (donor) stem cell transplantation, a new immune system grows in the patient from the transplanted donor stem cells and lymphocytes (type of immune cell). Donor lymphocytes, unlike the patient s own lymphocytes, often can recognize the patient s tumor cells as being foreign and destroy them. - It is thought that tumor shrinkage after stem cell transplantation is the result of donor T lymphocytes, or T cells. Some studies show that patients with tumors that have T cells are better able to keep tumor growth in check. - Patients who have had donor stem cell transplantation may have donor T cells in their tumors that can recognize and fight their cancer. Compared with donor T cells taken directly from the donor and infused into the patient, donor T cells found in patients tumors may be specific for the cancer cells and thus better able to attack tumor. Also, because the T cells found their way to the tumor, they may be less likely to recognize and attack non-tumor tissues than the T cells given in donor lymphocyte infusions. - The T cells may be especially effective at controlling tumor if they are given an additional stimulus to become active. Costimulation is the name of the body s natural process for providing an extra stimulus, and can be performed on cells in the laboratory. Costimulation can produce large numbers of activated cells that may be able to attack cancer cells and shrink tumors. Objectives: -To evaluate the ability of lymphocytes found in tumors from patients who have received donor stem cell transplants to control their tumor growth. Eligibility: -Patients between 18 and 75 years of age with a B-cell cancer that has continued to grow or recurred after remission following allogeneic stem cell transplantation. This includes patients who have received transplants from unrelated donors and cord blood. Design: - Immune cells are collected from patients blood and blood from their stem cell donor. - Patients undergo surgery to remove their tumor and a small piece of skin. In the laboratory, donor T cells are isolated from the tumor and costimulated to expand the number of cells and activate them. - The expanded, activated T cells as infused into the patient. - Patients have a needle biopsy and possibly surgery to remove a sample of remaining tumor for research studies. - Patients are followed at the NIH clinic 48 hours after the cell infusion, and again at 1, 2, 4, 8 and 12 weeks after the infusion. Tumor size is monitored every month with CT scans, and possibly also with a PET or bone marrow aspiration and biopsy, for the first 3 months after the cells are infused. Thereafter, visits are less frequent (every 3 months, then every 6 months, and then yearly) during a minimum 5-year follow-up. Detailed Description Background: - The prognosis for patients with B-cell lymphoid malignancies (BCL) with relapse or refractory disease after allogeneic hematopoietic stem cell transplantation (AlloHSCT) is poor. Effective therapy for patients who fail withdrawal of immune suppression and administration of donor lymphocyte infusions (DLI) has not been identified. - In the setting of recurrent or refractory BCL, the immunologic graft-versus-tumor (GVT) effect generated by unmanipulated donor lymphocytes is often not durable and can be accompanied by graft-versus-host disease (GVHD). - We have hypothesized that lymphocytes found in tumor after alloHSCT are of donor origin, and because they are tumor-derived, they may be tumor-specific in their homing and antigen specificity characteristics. Similarly, inpatients with bone marrow involvement with tumor, the marrow may be enriched with similarly tumor-specific T cells. Further, activation and expansion of these cells through CD3/CD28 costimulation may yield a more effective form of cell therapy than DLI after alloHSCT, with enhanced GVT effects and less GVHD. Objectives: - To evaluate the feasibility of isolating and expanding clinically relevant numbers of TDL from patients after alloHSCT. - To determine the safety, vis-a-vis infusion toxicities and/or GVHD, of administering TDL. Eligibility: - Adults with B cell malignancies with tumor that has not responded to successful T cell engraftment after alloHSCT, withdrawal of immune suppression and administration of donor lymphocyte infusion will be eligible for this trial. - Subjects must have a minimum of 1.5 cm of accessible tumor which is amenable to resection with minimal surgical morbidity and/or bone marrow tumor involvement. Design: - Subjects will have accessible lesion surgically resected and/or harvested via bone marrow aspiration. - Lymphocytes will be liberated and expanded using a co-stimulatory approach with anti-CD3/CD28 magnetic beads to generate TDL and/or marrow-TDL. - 1.0 x 10(6) - 1.0 x 10(8) TDL will be administered. - Subjects will be monitored for the development of infusion reactions (in-hospital for 24 hours after infusion), GVHD (weekly for four weeks then monthly) and tumor responses (monthly). - Two cohorts will be enrolled, with an arm evaluating TDL from resected tumor and an arm to evaluate marrow-TDL from tumor-involved bone marrow. For the TDL arm, 15 to 18 patients and up to 18 donors will be enrolled; for the marrow-TDL arem, 15 patients and up to 15 donors will be enrolled. Both arms will test the primary endpoints of feasibility (with at least 11 of 15 tumors yielding 1.0 x 10(6) TDL/kg meeting defined release criteria) and safety (primarily defined as having a no greater risk of developing grade II-IV acute GVHD by day 28 as standard therapy with unmanipulated DLI).
5 schema:endDate 2013-04-01T00:00:00Z
6 schema:keywords B-cell malignancy
7 CO
8 CT
9 Cell- and Tissue-Based Therapy
10 Fetal Blood
11 General Surgery
12 Graft vs Host Disease
13 Neoplasm
14 Organization and Administration
15 PET
16 Recurrence
17 T cell
18 T lymphocyte
19 Tissue Donor
20 Transplant
21 activated T cell
22 activated cell
23 acute graft-versus-host disease
24 additional stimulus
25 adoptive cell therapy
26 adult
27 age
28 allogeneic hematopoietic stem cell transplantation
29 allogeneic stem cell transplantation
30 antigen specificity
31 arm
32 attack
33 attack cancer cell
34 biopsy
35 blood
36 body
37 bone marrow
38 bone marrow aspiration
39 cancer cell
40 cell
41 cell cancer
42 cell engraftment
43 check
44 clinic
45 cm
46 cohort
47 control
48 costimulation
49 criterion
50 development
51 donor T cell
52 donor lymphocyte
53 donor lymphocyte infusion
54 donor origin
55 donor stem cell
56 effective form
57 effective therapy
58 eligibility
59 expansion
60 feasibility
61 fight
62 graft-versus-host-disease
63 graft-versus-tumor
64 graft-versus-tumor effect
65 great risk
66 homing
67 immune cell
68 immune suppression
69 immune system
70 infusion
71 inpatient
72 laboratory
73 large number
74 lesion
75 lymphocyte
76 lymphoid malignancy
77 magnetic bead
78 meeting
79 morbidity
80 name
81 natural process
82 needle biopsy
83 non-tumor tissue
84 patient
85 patient blood
86 patient tumor
87 primary endpoint
88 refractory disease
89 remission
90 research study
91 resected tumor
92 resection
93 safety
94 sample
95 setting
96 shrink
97 skin
98 small piece
99 standard therapy
100 stem cell
101 stem cell transplant
102 stem cell transplantation
103 stimulus
104 trial
105 tumor cell
106 tumor growth
107 tumor response
108 tumor shrinkage
109 tumor size
110 tumor-specific T cell
111 unrelated donor
112 visit
113 withdrawal
114 schema:name Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes
115 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01445132
116 schema:sdDatePublished 2019-03-07T15:24
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher Nbb90e980672449a084b792b0fc51e33e
119 schema:sponsor https://www.grid.ac/institutes/grid.410305.3
120 https://www.grid.ac/institutes/grid.48336.3a
121 schema:startDate 2007-01-01T00:00:00Z
122 schema:subjectOf sg:pub.10.1038/sj.bmt.1705074
123 https://doi.org/10.1056/nejm199304083281404
124 https://doi.org/10.1073/pnas.92.25.11810
125 schema:url https://clinicaltrials.gov/show/NCT01445132
126 sgo:license sg:explorer/license/
127 sgo:sdDataset clinical_trials
128 rdf:type schema:MedicalStudy
129 Nbb90e980672449a084b792b0fc51e33e schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
132 rdf:type schema:DefinedTerm
133 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
134 rdf:type schema:DefinedTerm
135 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
136 rdf:type schema:DefinedTerm
137 sg:pub.10.1038/sj.bmt.1705074 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053742519
138 https://doi.org/10.1038/sj.bmt.1705074
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1056/nejm199304083281404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043239598
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1073/pnas.92.25.11810 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006947674
143 rdf:type schema:CreativeWork
144 https://www.grid.ac/institutes/grid.410305.3 schema:Organization
145 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...